Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Macrophage Migration Inhibitory Factor (MIF)

Posted Apr 30 1997 5:00pm

Description of Invention:
The protein known as macrophage migration inhibitory factor (MIF) was one of the first cytokines to be discovered. Thirty-years ago it was described as a T-cell-derived factor that inhibited the random migration of macrophages in vitro. Today, MIF is known to be a mediator of the function of macrophages in host defense and its expression correlates with delayed hypersensitivity and cellular immunity. It plays an important role in the inflammatory response and is associated with cell differentiation. As with other lymphokines, MIF could have therapeutic values in stimulating the immune system and other cells. Hardly abundant from other sources, the high concentration of the protein that has been found in the eye lens could be a useful source for research. The present invention provides the DNA that encodes MIF. A related invention provides a method for isolating MIF from the ocular lens.

Applications:
* research reagent * therapeutic for inflammatory conditions * stimulation of the immune system

Advantages:
* abundant source * purified MIF

Inventors:
Graeme J Wistow (NEI)


Patent Status:
HHS, Reference No. E-090-1991/0
US, , Patent No. 5,656,737, Issued 12 Aug 1997
HHS, Reference No. E-090-1991/0
US, , Patent No. 5,328,990, Issued 12 Jul 1994
PCT, Application No. PCT/US92/03399 filed 26 Apr 1992


Related Technologies:
US, Patent No. 5,328,990, Issued 12 Jul 1994, Reference No. E-090-1991/0
EIR, Reference No. E-090-1991/0
US, Patent No. 5,656,737, Issued 12 Aug 1997, Reference No. E-090-1991/0
PCT, Application No. PCT/US92/03399 filed 26 Apr 1992, Reference No. E-090-1991/0


Relevant Publication:
  1. V Paralkar, G Wistow, "Cloning the human gene for macrophage migration inhibitory factor (MIF)," Genomics 19(1):48-51, 1994.


Licensing Status:
Available for licensing.


Portfolios:
Internal Medicine
Internal Medicine - Therapeutics
Ophthalmology
Ophthalmology - Therapeutics



For Additional Information Please Contact:
Surekha Vathyam Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: vathyams@mail.nih.gov
Phone: 301-435-4076
Fax: 301-402-0220


Ref No: 156

Updated: 05/1997

Post a comment
Write a comment: